{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:37:27Z","timestamp":1792514247221,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-178406"],"award-info":[{"award-number":["PJT-178406"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["#708177"],"award-info":[{"award-number":["#708177"]}],"id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015803","name":"BC Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiation therapy is commonly used to treat head and neck cancer patients, and response may be improved by combining radiation with preexisting medications. Based on recent preclinical and retrospective patient data, we hypothesized that antihypertensive drugs may improve radiotherapy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analyses were conducted on 1077 oropharyngeal squamous cell carcinoma and 608 nasopharyngeal carcinoma patients, all of whom received radiation therapy. Univariate and multivariate analyses were conducted to assess overall survival, disease-specific survival, and locoregional control for cancer patients taking angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors, calcium channel blockers, or beta blockers compared with propensity score\u2013matched groups of patients not taking these medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Oropharyngeal squamous cell carcinoma patients taking antihypertensive medications were statistically older and had higher Charlson Comorbidity Indices at diagnosis. However, these patients had statistically significant improved overall survival, disease-specific survival, and locoregional control compared with propensity score\u2013matched oropharyngeal squamous cell carcinoma patients who were not taking antihypertensive medications, with ARB users showing the greatest improvements. Antihypertensive drugs did not affect outcomes in the nasopharyngeal carcinoma patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of antihypertensive medications, and particularly ARBs, was associated with improved outcomes in oropharyngeal squamous cell carcinoma patients who had more advanced age and higher Charlson Comorbidity Indices at diagnosis. This study supports future prospective testing of ARBs in conjunction with radiation therapy in this group of higher risk oropharyngeal squamous cell carcinoma patients. Additionally, this study illustrates the need to use propensity score matching to identify patient subgroups that may benefit from a given treatment in retrospective analyses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djaf056","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:21:21Z","timestamp":1741044081000},"page":"1410-1420","source":"Crossref","is-referenced-by-count":5,"title":["Antihypertensive drugs and survival outcomes in oropharyngeal squamous cell carcinoma patients"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-7760","authenticated-orcid":false,"given":"Che-Min","family":"Lee","sequence":"first","affiliation":[{"name":"Integrative Oncology Department, BC Cancer , Vancouver, BC,","place":["Canada"]},{"name":"Interdisciplinary Oncology Program, University of British Columbia , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan J","family":"Wadsworth","sequence":"additional","affiliation":[{"name":"Integrative Oncology Department, BC Cancer , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Urban","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, BC Cancer , Vancouver, BC,","place":["Canada"]},{"name":"Department of Medicine, University of British Columbia , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8060-4039","authenticated-orcid":false,"given":"Meredith A","family":"Clark","sequence":"additional","affiliation":[{"name":"Integrative Oncology Department, BC Cancer , Vancouver, BC,","place":["Canada"]},{"name":"Interdisciplinary Oncology Program, University of British Columbia , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocky","family":"Shi","sequence":"additional","affiliation":[{"name":"Integrative Oncology Department, BC Cancer , Vancouver, BC,","place":["Canada"]},{"name":"Interdisciplinary Oncology Program, University of British Columbia , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daegan","family":"Sit","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, BC Cancer , Vancouver, BC,","place":["Canada"]},{"name":"Department of Medicine, University of British Columbia , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah N","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, BC Cancer , Vancouver, BC,","place":["Canada"]},{"name":"Department of Medicine, University of British Columbia , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4066-6507","authenticated-orcid":false,"given":"Kevin L","family":"Bennewith","sequence":"additional","affiliation":[{"name":"Integrative Oncology Department, BC Cancer , Vancouver, BC,","place":["Canada"]},{"name":"Interdisciplinary Oncology Program, University of British Columbia , Vancouver, BC,","place":["Canada"]},{"name":"Pathology and Laboratory Medicine, University of British Columbia , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025070619564304900_djaf056-B1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.oraloncology.2010.03.009","article-title":"Oral cancer: clinical features","volume":"46","author":"Bagan","year":"2010","journal-title":"Oral Oncol"},{"issue":"Suppl 7","key":"2025070619564304900_djaf056-B2","doi-asserted-by":"publisher","first-page":"Vii308","DOI":"10.1093\/annonc\/mdq277","article-title":"Nasopharyngeal carcinoma","volume":"21","author":"Chan","year":"2010","journal-title":"Anns Oncol."},{"key":"2025070619564304900_djaf056-B3","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1158\/1078-0432.ccr-18-0236","article-title":"Renin\u2013Angiotensin system inhibitors to mitigate cancer treatment\u2013related adverse events","volume":"24","author":"Pinter","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025070619564304900_djaf056-B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2020.07.015","article-title":"Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation","volume":"493","author":"Wadsworth","year":"2020","journal-title":"Cancer Letters"},{"key":"2025070619564304900_djaf056-B5","doi-asserted-by":"publisher","first-page":"e6394","DOI":"10.1097\/md.0000000000006394","article-title":"Do renin\u2013angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?","volume":"96","author":"Sun","year":"2017","journal-title":"Medicine"},{"key":"2025070619564304900_djaf056-B6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.clgc.2022.04.012","article-title":"Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors","volume":"20","author":"Nuzzo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2025070619564304900_djaf056-B7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1593\/tlo.13346","article-title":"Exposure to ACEI\/ARB and \u03b2-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer","volume":"6","author":"Engineer","year":"2013","journal-title":"Translational Oncology"},{"key":"2025070619564304900_djaf056-B8","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/cncr.30079","article-title":"Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","volume":"122","author":"Morris","year":"2016","journal-title":"Cancer"},{"key":"2025070619564304900_djaf056-B9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with Losartan followed by chemoradiotherapy for locally advanced pancreatic cancer","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025070619564304900_djaf056-B10","doi-asserted-by":"publisher","first-page":"e8188","DOI":"10.7717\/peerj.8188","article-title":"Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension","volume":"7","author":"Wei","year":"2019","journal-title":"PeerJ"},{"key":"2025070619564304900_djaf056-B11","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1002\/hed.26809","article-title":"Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer","volume":"43","author":"Stokes","year":"2021","journal-title":"Head Neck"},{"key":"2025070619564304900_djaf056-B12","doi-asserted-by":"publisher","first-page":"e0260772","DOI":"10.1371\/journal.pone.0260772","article-title":"Angiotensin II receptor blockers and oral squamous cell carcinoma survival: a propensity-score-matched cohort study","volume":"16","author":"Wu","year":"2021","journal-title":"PLoS ONE"},{"key":"2025070619564304900_djaf056-B13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s12094-016-1608-8","article-title":"Postdiagnostic use of \u03b2-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: An observational study of 10,414 person\u2013years of follow-up","volume":"19","author":"Kim","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"2025070619564304900_djaf056-B14","doi-asserted-by":"publisher","first-page":"e2200490","DOI":"10.1200\/po.22.00490","article-title":"Beta-Blocker use is associated with worse relapse-free survival in patients with head and neck cancer","volume":"7","author":"Chen","year":"2023","journal-title":"J Clin Oncol Precis Oncol"},{"key":"2025070619564304900_djaf056-B15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.radonc.2020.08.005","article-title":"Population-based outcomes by immunosuppressed status in patients undergoing radiotherapy for oropharyngeal cancer","volume":"151","author":"Hamilton","year":"2020","journal-title":"Radiother Oncol"},{"key":"2025070619564304900_djaf056-B16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/coc.0000000000000992","article-title":"Population-based long-term outcomes for squamous cell carcinoma of the nasal cavity","volume":"46","author":"Hamilton","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"2025070619564304900_djaf056-B17","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on cancer: the 7th Edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2025070619564304900_djaf056-B18","author":"R Core Team","year":"2024"},{"key":"2025070619564304900_djaf056-B19","author":"Greifer","year":"2024"},{"key":"2025070619564304900_djaf056-B20","author":"Wickham","year":"2023"},{"key":"2025070619564304900_djaf056-B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"2025070619564304900_djaf056-B22","author":"Hebbali","year":"2024"},{"key":"2025070619564304900_djaf056-B23","author":"Therneau","year":"2024"},{"key":"2025070619564304900_djaf056-B24","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"2025070619564304900_djaf056-B25","author":"Rich","year":"2023"},{"key":"2025070619564304900_djaf056-B26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/tac.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Autom Control"},{"key":"2025070619564304900_djaf056-B27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"2025070619564304900_djaf056-B28","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/sim.3150","article-title":"A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003","volume":"27","author":"Austin","year":"2008","journal-title":"Stat Med"},{"key":"2025070619564304900_djaf056-B29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2025070619564304900_djaf056-B30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1524-4733.2006.00130.x","article-title":"Too much Ado about propensity score models? Comparing methods of propensity score matching","volume":"9","author":"Baser","year":"2006","journal-title":"Value Health"},{"key":"2025070619564304900_djaf056-B31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","article-title":"Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies","volume":"121","author":"Yap","year":"2018","journal-title":"Br J Anaesth"},{"key":"2025070619564304900_djaf056-B32","doi-asserted-by":"publisher","first-page":"e13493","DOI":"10.1111\/eci.13493","article-title":"Effects of hypertension on cancer survival: a meta-analysis","volume":"51","author":"Petrelli","year":"2021","journal-title":"European Journal of Clinical Investigation"},{"key":"2025070619564304900_djaf056-B33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.phrs.2019.01.037","article-title":"Intriguing relationship between antihypertensive therapy and cancer","volume":"141","author":"Tadic","year":"2019","journal-title":"Pharmacol Res"},{"key":"2025070619564304900_djaf056-B34","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41568-024-00708-4","article-title":"Why do patients with cancer die?","volume":"24","author":"Boire","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"2025070619564304900_djaf056-B35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1472-8206.2009.00752.x","article-title":"Antihypertensive drugs and risk of venous thromboembolism: results from the EDITH case\u2013control study","volume":"24","author":"Belattar","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"2025070619564304900_djaf056-B36","doi-asserted-by":"publisher","first-page":"18632","DOI":"10.1073\/pnas.1318415110","article-title":"Combining two strategies to improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulos","year":"2013","journal-title":"Proc Natl Acad Sci"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf056\/62856989\/djaf056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/7\/1410\/62856989\/djaf056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/7\/1410\/62856989\/djaf056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T19:56:48Z","timestamp":1751831808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/7\/1410\/8105630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf056","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,12]]}}}